Huma Therapeutics Limited Sustainability Profile
Huma Therapeutics Limited, commonly referred to as Huma, is a pioneering health technology company headquartered in Great Britain. Founded in 2016, Huma operates primarily in the digital health industry, focusing on transforming patient care through innovative solutions. The company is renowned for its advanced platform that integrates real-time health data, enabling personalised treatment and proactive disease management. Huma's core offerings include remote patient monitoring and data analytics services, which stand out for their ability to enhance clinical decision-making and improve patient outcomes. With a strong presence in the UK and expanding operations across Europe and beyond, Huma has established itself as a leader in the digital health space. Notable achievements include partnerships with major healthcare providers, positioning Huma at the forefront of the digital transformation in healthcare.
DitchCarbon Score
How does Huma Therapeutics Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Telecommunications Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Huma Therapeutics Limited's score of 29 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Huma Therapeutics Limited's reported carbon emissions
In 2022, Huma Therapeutics Limited reported total carbon emissions of approximately 1,018,000 kg CO2e. This figure includes 5,000 kg CO2e from Scope 2 emissions, while Scope 1 emissions were recorded at zero. The majority of emissions, about 1,013,000 kg CO2e, were attributed to Scope 3, which encompasses indirect emissions from the company's value chain. Notable contributors to Scope 3 emissions included purchased goods and services (approximately 501,700 kg CO2e), employee commuting (about 215,900 kg CO2e), and business travel (around 210,000 kg CO2e). Huma Therapeutics has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2022 as the baseline year. This target has been validated by the Science Based Targets initiative (SBTi) and is consistent with the reductions necessary to limit global warming to 1.5°C. The company also plans to measure and address its Scope 3 emissions as part of its sustainability strategy. These commitments reflect Huma Therapeutics Limited's proactive approach to climate action within the healthcare sector, demonstrating a clear intention to mitigate its environmental impact.
How Carbon Intensive is Huma Therapeutics Limited's Industry?
How Carbon Intensive is Huma Therapeutics Limited's Location?
Huma Therapeutics Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Huma Therapeutics Limited has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Huma Therapeutics Limited's sustainability data and climate commitments